The joint healthcare venture between Amazon (NSDQ:AMZN), Berkshire Hathaway and J.P. Morgan Chase said this week it named Brigham and Women’s Hospital surgeon, New Yorker magazine staff writer and bestselling author Dr. Atul Gawande as its CEO, effective July 9.
The joint venture said that the newly formed company will be headquartered in Boston, and will operate as an independent entity free from profit-making incentives and constraints.
Dr. Gawande also serves as a professor of Harvard Medical School and the Harvard T.H. Chan School of Public Health, and is the founding executive director of health systems innovation center Ariadne labs.
“I’m thrilled to be named CEO of this healthcare initiative. I have devoted my public health career to building scalable solutions for better healthcare delivery that are saving lives, reducing suffering, and eliminating wasteful spending both in the US and across the world. Now I have the backing of these remarkable organizations to pursue this mission with even greater impact for more than a million people, and in doing so incubate better models of care for all. This work will take time but must be done. The system is broken, and better is possible,” Dr. Gawande said in a prepared statement.
“As employers and as leaders, addressing healthcare is one of the most important things we can do for our employees and their families, as well as for the communities where we all work and live. Together, we have the talent and resources to make things better, and it is our responsibility to do so. We’re so grateful for the countless statements of support and offers to help and participate, and we’re so fortunate to have attracted such an extraordinary leader and innovator as Atul,” JPMorgan Chase chair & CEO Jamie Dimon said in a press release.
“We said at the outset that the degree of difficulty is high and success is going to require an expert’s knowledge, a beginner’s mind, and a long-term orientation. Atul embodies all three, and we’re starting strong as we move forward in this challenging and worthwhile endeavor,” Amazon founder & CEO Jeff Bezos said in a prepared release.
“Talent and dedication were manifest among the many professionals we interviewed. All felt that better care can be delivered and that rising costs can be checked. Jamie, Jeff and I are confident that we have found in Atul the leader who will get this important job done,” Berkshire Hathaway chair and CEO Warren Buffett said in prepared remarks.
Woods previously served as an executive officer at IsoRay, operating as a VP from 2006 to 2008, then being lifted to chief operating officer, a position they held until January 2010. She served as a senior consultant with IsoRay beginning in February 2016, the company said.
Outside of IsoRay, Woods operated as a principal ad medical device consultant company Medvio, and has held positions as CEO of cancer treatment management company Pro-Qura.
“The board and employees have high confidence in Lori Woods that has been built through the years that she has served at IsoRay. Although she is currently serving as CEO on an interim basis, we believe that Ms. Woods’ experience and credibility in the industry and recognized leadership skills with the management team will maintain the momentum the company has established of improving revenues over the past five quarters. As part of her employment agreement, the company has issued Ms. Woods options which have no vesting exercisable within the initial six-month period as the board wants to align her performance over the next six-month period with the interests of our shareholders,” board chair Mick McCormick said in a prepared statement.
“I thank the board for the opportunity to lead IsoRay at this exciting time and look forward to continuing and expanding the many programs that have been put in place to propel growth over the past two years. This includes the upcoming FDA decision on the use of GammaTile for brain cancer, the development of the Build Blu disposable loader for prostate brachytherapy procedures, and the momentum that is continuing to build in the sales pipeline. We believe that the investments that have been made in our two-pronged growth strategy that targets the prostate brachytherapy market through investment and support for the industry while also promoting development of new surgical applications are beginning to pay off, as evidenced by the year-over-year revenue increases of the past five quarters. Everyone at IsoRay remains keenly focused on achieving our goals and I’m confident in our ability to do so,” Woods said in a press release.
AirXpanders (ASX:AXP) said last week it named former Boston Scientific (NYSE:BSX) vice president Frank Grillo as its new president and chief executive officer, effective June 12. Grillo will also join the company’s board of directors.
Prior to joining AirXpanders, Grillo served in multiple roles with Boston Scientific including marketing VP for its women’s health, urology and gynecology division.
Prior to joining Boston Scientific, Grillo served as biz dev VP of Kyphon, which was sold to Medtronic for $4.2 billion in 2007, and joined Intuitive Surgical (NSDQ:ISRG) where they acted as marketing and new biz dev VP. He also served as prez and CEO of MRI Interventions (OTC:MRIC).
“We are delighted to have attracted and hired such a high-caliber CEO. Frank’s experience and track record in all aspects of the medical device business, including marketing, business development, sales growth and operational efficiency will serve our company well. The company has made excellent progress over the last few months in reducing costs and improving the efficiency of the sales process. I would like to personally thank Scott Murcray, our interim CEO, for his outstanding leadership during this period,” co-founder and board chair Barry Cheskin said in a prepared statement.
“I am excited to join AirXpanders, and to continue driving the adoption of the AeroForm tissue expander. AeroForm is an innovative product, uniquely suited to transform post- mastectomy tissue expansion. The product is highly innovative, the market is significant, and surgeons are very interested in the ability to streamline this important step in recovery for their patients. I am excited to take on the leadership of the company and pursue the great opportunity in front of us,” Grillo said in a press release.
France-based life sciences and health cluster Medicen said last week it appointed Stéphane Roques as its new CEO.
Prior to joining Medicen, Roques spent six years at Arthur Anderson and has managed innovation and health organizations including AFM-Téléthon and MSF – Doctors without Borders, Medicen said.
“Stéphane will bring a new managerial dimension to the cluster, a wealth of knowledge in the health ecosystem and a pragmatic ambition to further company development in order to make the Paris region one of the world leaders in health,” Medicen Paris region prez Christian Lajoux said in a press release.
“I am passionate about innovation and health. I have always been committed to serving the public interest alongside public and private actors, whether they be doctors, researchers, patients, entrepreneurs or investors. I am convinced that the convergence of their common interests can shape a new world and be a source of economic and societal value. I am proud to join the Medicen team to take up this formidable challenge, ” Roques said in a prepared statement.
Frushell headed Pivot Medical during its acquisition by Stryker (NYSE:SYK), San Jose, Calif.-based Avantis said. Frushell will replace outgoing prez and CEO Anthony DiTonno, who will now serve as board chair.
The company also announced it lifted R&D and manufacturing VP Salmaan Hameed as its new chief technology officer.
“We’re excited to have Matt join the team and take the company to the next level,” DiTonno said in a prepared release.
“The Third Eye Panoramic is an elegant medical innovation that makes a real difference in healthcare and is easy for clinicians to adopt and use. I’m looking forward to working with Tony, Salmaan, and the entire team to bring this remarkable technology to physicians and patients and to continue advancements in cancer detection. The recent announcement of our commercial partnership with Pentax Medical, an industry leader in diagnostic and therapeutic endoscopy, underscores the strength of our innovative products,” Freshell said in a prepared statement.